XML 70 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions and Divestiture (Narrative) (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 11 Months Ended 12 Months Ended
Jan. 10, 2020
USD ($)
$ / shares
Oct. 31, 2019
USD ($)
medicine
Feb. 28, 2019
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]                              
Acquired IPR&D       $ 0.0 $ 77.7 $ 25.0 $ 136.9 $ 329.4 $ 30.0 $ 1,624.5 $ 0.0   $ 239.6 $ 1,983.9 $ 1,112.6
Gain related to disposition                         309.8 0.0 0.0
Loxo Oncology, Inc.                              
Business Acquisition [Line Items]                              
Consideration transferred     $ 6,920.0                        
Revenue                       $ 136.7      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China                              
Business Acquisition [Line Items]                              
Gain related to disposition                         $ 309.8 $ 0.0 $ 0.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China | Eddingpharm                              
Business Acquisition [Line Items]                              
Number of legacy antibiotic medicines rights sold | medicine   2                          
Proceeds from divestiture of businesses, net of cash divested   $ 354.8                          
Disposal group, not discontinued operation, payment to be received   $ 40.3                          
Gain related to disposition       $ 309.8                      
Subsequent Event | Dermira                              
Business Acquisition [Line Items]                              
Consideration transferred $ 1,100.0                            
Cash paid per acquiree share (in usd per share) | $ / shares $ 18.75